BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/6/2021 12:29:29 PM | Browse: 47 | Download: 75
Publication Name World Journal of Clinical Cases
Manuscript ID 58038
Country/Territory China
Received
2020-09-08 16:50
Peer-Review Started
2020-09-08 16:50
To Make the First Decision
Return for Revision
2020-11-20 06:53
Revised
2020-12-03 11:55
Second Decision
2020-12-22 12:46
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-12-23 05:10
Articles in Press
2020-12-23 05:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
2021-01-06 23:57
Typeset the Manuscript
2021-02-04 03:29
Publish the Manuscript Online
2021-02-06 11:08
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Efficacy of afatinib in patients with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report
Manuscript Source Unsolicited Manuscript
All Author List Shu-Yan He, Qing-Feng Lin, Jie Chen, Gui-Ping Yu, Jun-Ling Zhang and Dong Shen
Funding Agency and Grant Number
Corresponding Author Dong Shen, PhD, Chief Doctor, Department of Medical Oncology, The Jiangyin Clinical College of Xuzhou Medical University, No. 163 Shoushan Road, Jiangyin 214400, Jiangsu , China. sdshendong@126.com
Key Words EGFR G724S and R776H; Afatinib; Non-small-cell lung cancer; Case report
Core Tip EGFR represents the first identified targetable oncogenic driver discovered in NSCLC. The most common EGFR mutations are in-frame deletions in exon 19 and exon 21. However, rare mutations were found in nearly 10-15% of EGFR-positive NSCLC and NSCLC with rare co-mutations had significantly different responses to EGFR TKI. Herein, we described a rare case of rare EGFR G724S/R776H mutations and amplification in a NSCLC responding to afatinib.
Publish Date 2021-02-06 11:08
Citation He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in patients with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335
Url https://www.wjgnet.com/2307-8960/full/v9/i6/1329.htm
DOI https://dx.doi.org/10.12998/wjcc.v9.i6.1329
Full Article (PDF) WJCC-9-1329.pdf
Full Article (Word) WJCC-9-1329.docx
Manuscript File 58038_Auto_Edited_WangTQ.docx
Answering Reviewers 58038-Answering reviewers.pdf
Audio Core Tip 58038-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 58038-Conflict-of-interest statement.pdf
Copyright License Agreement 58038-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 58038-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate 58038-Language certificate.pdf
Peer-review Report 58038-Peer-review(s).pdf
Scientific Misconduct Check 58038-Scientific misconduct check.pdf
Scientific Editor Work List 58038-Scientific editor work list.pdf